Colorado Springs, CO, United States of America

Amy Beth Dounay

USPTO Granted Patents = 21 

 

 

Average Co-Inventor Count = 8.6

ph-index = 5

Forward Citations = 67(Granted Patents)


Location History:

  • Ledyard, CT (US) (2012 - 2013)
  • Colorado Springs, CO (US) (2014 - 2024)

Company Filing History:


Years Active: 2012-2024

Loading Chart...
Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents

Title: Amy Beth Dounay: Pioneering Innovator in Pharmaceutical Sciences

Introduction:

Amy Beth Dounay, a distinguished inventor based in Colorado Springs, CO, has made significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 21 patents, her groundbreaking work has focused on developing compounds for the treatment of various neurological and psychiatric disorders.

Latest Patents:

One of Dounay's latest patents revolves around "Heteroaromatic Compounds and Their Use as Dopamine D1 Ligands." This invention introduces compounds of Formula I and their pharmaceutical salts, showcasing their efficacy in treating D1-mediated disorders such as schizophrenia, cognitive impairment, ADHD, impulsivity, and various other conditions.

Career Highlights:

Currently employed at Pfizer Corporation, Dounay's expertise and dedication have been instrumental in advancing novel drug therapies. Her innovative approach to drug development has not only earned her recognition within the industry but has also paved the way for transformative treatments in neurology and psychiatry.

Collaborations:

Throughout her career, Dounay has collaborated with esteemed professionals in the field, including her coworkers Jennifer Elizabeth Davoren and Ivan Viktorovich Efremov. Together, they have synergized their efforts to drive innovation and bring forth new solutions to complex medical challenges.

Conclusion:

In conclusion, Amy Beth Dounay stands out as a trailblazing inventor whose relentless pursuit of excellence has reshaped the landscape of pharmaceutical research. Her profound impact on the development of therapeutic compounds underscores her commitment to improving the quality of life for individuals affected by neurological and psychiatric disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…